Product image of Ledraxen (Enoxaparin Sodium) supplied by GNH India

Ledraxen

Active Ingredient:
Enoxaparin Sodium
Origin:
EU

Ledraxen (Enoxaparin Sodium)

Enoxaparin sodium, the active ingredient in Ledraxen, is a low molecular weight heparin presented as a sterile injectable solution for subcutaneous, intravenous, and haemodialysis use. It is employed to prevent and treat deep vein thrombosis, pulmonary embolism, and to provide anticoagulation during haemodialysis procedures.

GNH India supplies Ledraxen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Venipharm

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ledraxen, a low molecular weight heparin, is indicated for several thromboembolic conditions.

  • Deep vein thrombosis (DVT) prophylaxis: prevents clot formation in surgical patients at risk of DVT.
  • Acute deep vein thrombosis treatment: facilitates clot resolution and reduces propagation.
  • Pulmonary embolism prevention and treatment: lowers risk of embolic events in high‑risk patients.
  • Anticoagulation during haemodialysis: maintains circuit patency by inhibiting clotting.

How It Works

  • Enoxaparin sodium binds to antithrombin III, accelerating its inhibition of factor Xa and, to a lesser extent, thrombin (factor IIa). By reducing the generation of thrombin and subsequent fibrin formation, it interrupts the coagulation cascade, thereby preventing the development and extension of intravascular clots.

Side Effects

Enoxaparin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Injection site reactions: erythema, pain, or bruising at the administration site.
  • Minor bleeding: nosebleeds, gum bleeding, or easy bruising.
  • Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects

  • Major hemorrhage: internal bleeding requiring medical intervention.
  • Thrombocytopenia: significant drop in platelet count, potentially leading to bleeding.
  • Allergic reactions: rash, urticaria, or anaphylaxis.
  • Elevated liver enzymes: abnormal hepatic function tests.

Precautions & Warnings

When using Ledraxen, certain precautions should be observed to minimize risks.

  • Renal impairment: adjust dose or monitor anti‑Xa levels in patients with reduced kidney function.
  • Concomitant anticoagulants: avoid or closely monitor when used with other anticoagulant or antiplatelet agents.
  • Recent surgery or trauma: assess bleeding risk before initiating therapy.
  • Pregnancy and lactation: use only if the potential benefit outweighs the risk, as safety data are limited.
  • Spinal/epidural procedures: discontinue before neuraxial anesthesia to reduce spinal hematoma risk.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Enoxaparin can interact with several medications, affecting its anticoagulant effect.

Major Interactions (Avoid)

  • Warfarin: combined use markedly increases bleeding risk.
  • Direct oral anticoagulants (e.g., rivaroxaban, apixaban): additive anticoagulation may cause severe hemorrhage.
  • Thrombolytic agents (e.g., alteplase): heightened risk of major bleeding.

Moderate Interactions (Monitor Closely)

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase minor bleeding.
  • Antiplatelet drugs (e.g., aspirin, clopidogrel): monitor for enhanced bleeding.
  • Heparin products: overlapping anticoagulant effect requires careful monitoring.

Frequently Asked Questions

Ledraxen is an injectable formulation of enoxaparin sodium used as an anticoagulant. It is prescribed to prevent deep vein thrombosis in patients undergoing surgery, to treat acute DVT, to prevent and treat pulmonary embolism, and to provide anticoagulation during haemodialysis procedures.

Enoxaparin sodium enhances the activity of antithrombin III, which in turn inhibits factor Xa and, to a lesser extent, thrombin (factor IIa). This inhibition reduces the conversion of fibrinogen to fibrin, thereby interrupting clot formation and limiting the growth of existing clots.

The dosage of Ledraxen is individualized and determined by the prescribing healthcare professional based on the specific indication, patient weight, renal function, and clinical situation. No standard dose is provided here; the prescriber will set the appropriate regimen.

Safety data for enoxaparin in pregnancy and lactation are limited. It may be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and breastfeeding decisions should be made in consultation with a healthcare provider.

To order Ledraxen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Ledraxen (enoxaparin) is a low molecular weight heparin, offering more predictable pharmacokinetics and once- or twice‑daily dosing without routine laboratory monitoring, unlike unfractionated heparin which requires continuous infusion and frequent aPTT checks. Both provide anticoagulation, but enoxaparin generally has a lower risk of heparin‑induced thrombocytopenia.

Ledraxen should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. Maintaining the cold chain preserves the stability and efficacy of the injectable solution.

Ledraxen is administered by subcutaneous injection, intravenous injection, or through the haemodialysis circuit, depending on the clinical indication. The injection site should be rotated for subcutaneous use, and aseptic technique must be followed for all routes of administration.

The most serious risks include major bleeding events such as internal hemorrhage, spinal or epidural hematoma, and severe thrombocytopenia that can lead to uncontrolled bleeding. Prompt medical attention is required if signs of serious bleeding or a sudden drop in platelet count occur.

Ledraxen should be avoided in patients with known hypersensitivity to enoxaparin or other low molecular weight heparins, active major bleeding, or a history of heparin‑induced thrombocytopenia. Caution is also advised for individuals with severe renal impairment or those scheduled for neuraxial anesthesia.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Enoxaparin Sodium

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT